Tekla Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Tekla Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$848K	Buy	256,888 +198,351	+339%	+$583K	0.03%	131
2023 Q1	$167K	Hold	58,537	–	–	0.01%	168
2022 Q4	$426K	Buy	+58,537	New	+$382K	0.02%	151
2022 Q3	–	Sell	-58,537	Closed	-$287K	–	176
2022 Q2	$287K	Sell	58,537 -18,756	-24%	-$183K	0.01%	165
2022 Q1	$1.83M	Hold	77,293	–	–	0.06%	128
2021 Q4	$1.37M	Buy	77,293 +33,395	+76%	+$662K	0.04%	139
2021 Q3	$1.24M	Buy	+43,898	New	+$832K	0.04%	147

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tekla Capital Management's FULC Position: Q2 2023 in Review

Tekla Capital Management increased its Fulcrum Therapeutics (FULC) stake by 339% in Q2 2023, buying an estimated $583K and bringing the position to 256,888 shares worth $848K. The position accounts for 0.03% of the portfolio, ranked #131.

Tekla Capital Management first reported a position in FULC in Q3 2021 and has held it in 7 quarters since. The position peaked at $1.83M in Q1 2022. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

Tekla Capital Management held 256,888 shares of Fulcrum Therapeutics worth $848K as of Q2 2023.
Tekla Capital Management bought 198,351 Fulcrum Therapeutics shares in Q2 2023, an estimated $583K.
Fulcrum Therapeutics made up 0.03% of Tekla Capital Management's portfolio in Q2 2023, its #131 holding.
Tekla Capital Management first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 7 quarters since.
Tekla Capital Management's Fulcrum Therapeutics position peaked at $1.83M in Q1 2022.
88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.